Clinical Trial Update: Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 [Phase 2]

View source ↗

Summary

Omeros' Phase 2 safety study of OMS721 in immunoglobulin A nephropathy, lupus nephritis, membranous nephropathy, and C3 glomerulopathy including dense deposit d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• C3 Glomerulopathy
• Dense Deposit Disease
• Iga Nephropathy
• Lupus Nephritis
• Membranous Nephropathy

Drugs mentioned

• OMS721 (narsoplimab)

Snippet

Sponsor: Omeros Corporation | Conditions: IgAN, LN | Phase 2 | Status: TERMINATED | Results posted: 2026-03-30